

Express Mail No.: EL 452 481 122 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:
LITTLE and KIPRIYANOV

Serial No.: 09/674,794

Group Art Unit: To be assigned

I.A. Filing Date: May 5, 1999

Examiner: To be assigned

For: *Multivalent Antibody Constructs*

Attorney Docket No.: 8484-089-999

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notification of Missing Requirements mailed May 22, 2001, Applicants attorney, in connection with the above-identified patent application, submits herewith a Sequence Listing in computer readable form in compliance with 37 C.F.R. §§ 1.821(e).

I hereby state that the content of the paper copy of the Sequence Listing submitted on November 3, 2000 and the computer readable copy of the Sequence Listing submitted herewith, in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

In accordance with the Rules of Practice, please enter the following amendments and consider the remarks below prior to the examination of the above-captioned application.

IN THE SPECIFICATION

On page 8, please replace the paragraph beginning, “The plasmids pHOG- α CD19 and pHOG-dmOKT3 which code for the scFv fragments derived from the hybridoma...” with the following paragraph:

The plasmids pHOG- α CD19 and pHOG-dmOKT3 which code for the scFv fragments derived from the hybridoma HD37 which is specific to human CD19 (Kipriyanov *et al.*, 1996, *J.-Immunol. Meth.* 196:51-62) and from the hybridoma OKT3 which is specific to human CD3 (Kipriyanov *et al.*, 1997, *Protein Eng.* 10:445-453), respectively, were used for the construction of expression plasmids for a single-chain F_v antibody construct. A PCR